Life Extension Magazine March 2005
In The News
Several chemical compounds based on curcumin have demonstrated very promising anti-cancer activity in the laboratory, according to reports from scientists at Emory University in Atlanta.* Curcumin is a bioactive compound present in turmeric, best known as the canary-yellow spice that forms the basis of Indian curry dishes.
Known to exhibit powerful anti-cancer, anti-inflammatory and antioxidant properties, curcumin may reduce the risk of cancer, heart disease, and Alzheimer’s disease, among other disorders. In laboratory tests performed at the National Cancer Institute (NCI), at least nine of more than a dozen laboratory-created curcumin analogs showed “a moderate degree of anti-cancer activity,” according to the Emory researchers. Three of the new curcumin derivatives “exhibited a high degree of cytotoxicity” in testing performed at NCI. These same analogs inhibited tumor cell growth better than cisplatin, a commonly used chemotherapy drug.
In laboratory tests performed at Emory, eight of the new compounds exhibited “a high degree” of anti-cancer activity, including effectiveness at preventing or interfering with angiogenesis, the process by which tumors supply themselves with nutrients that fuel their growth. Anti-angiogenic activity is of special interest to oncologists, because eliminating the vessels that supply blood to a tumor effectively strangles the tumor while preventing damage to surrounding tissues.
Of the numerous potentially effective synthetic compounds tested, the researchers deemed one especially promising. Tested on live mice bred to serve as human breast cancer models, the chemical was well tolerated by the rodents and effectively reduced the size of the animals’ tumors. Researchers believe that this curcumin analog may be a candidate for development as a new anti-cancer drug.
* Adams BK, Ferstl EM, Davis MC, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti- angiogenesis agents. Bioorg Med Chem. 2004 Jul 15;12(14):3871-83.
Researchers in New Zealand have shown that the lactoferrin is uniquely able to increase the proliferation of human osteoblast cells, which are crucial to building bone.* Their findings may hold enormous significance in preventing and treating osteoporosis, a metabolic bone disease that is considered difficult to treat.
Lactoferrin, a secretory protein found in milk, saliva, nasal and gastrointestinal secretions, and other sources, is thought to provide broad-spectrum defense against bacteria, fungi, protozoa, and viruses. Lactoferrin exhibits immunomodulatory, anti-inflammatory, anti-tumorigenic, and anti-infective activity, and also promotes wound healing.
Osteoblasts are bone cells that promote bone growth, while osteoclasts counter osteoblast activity by regulating the resorption or breakdown of bone. Traditional treatments for osteoporosis inhibit bone resorption but do not stimulate bone growth. Researchers at the University of Auckland, New Zealand, have found that when nourished with lactoferrin at physiological concentrations in vitro, human osteoblast-like cells undergo increased proliferation and reduced cell death, while osteoclast proliferation is diminished. Lacto-ferrin also exhibits these effects more potently than other naturally occurring growth factors. Concen-trations of lactoferrin in excess of physiological levels stimulate osteoblast proliferation even more, up to a factor of five times, and reduce cell death by up to 70%. Lactoferrin is a prominent component of whey protein and may also be obtained in synthetic form that is bioidentical to human lactoferrin.
The researchers believe that lactoferrin’s role in promoting the physiological growth of bone holds important implications for preventing and slowing the progression of osteoporosis, which afflicts some 20 million American adults, often leading to crippling or fatal hip fractures.
—Linda M. Smith, RN
* Cornish J, Callon KE, Naot D, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology. 2004 Sep;145(9):4366-74.
Researchers from the Netherlands have found that increased dietary intake of vitamin K2 is associated with a lower risk of coronary heart disease.
The scientists sought to test the hypothesis that vitamin K deficiency leads to increased calcification of atherosclerotic lesions, thereby raising the risk of heart disease. They examined data obtained in the Rotterdam Study, which enrolled 4,983 men and women aged 55 and older from 1990 to 1993. The current study analyzed the dietary data of 4,807 participants with no history of heart attack, and followed them until 2000.*
While levels of both vitamin K1 (phylloquinone) and vitamin K2 were associated with beneficial high-density lipoprotein (HDL), only vitamin K2 was also associated with a decrease in total cholesterol. Compared to those whose vitamin K2 intake was in the lowest third of all participants, subjects whose intake was in the top third had a 41% reduction in fatal and nonfatal heart attacks, sudden cardiac deaths, and other forms of ischemic heart disease. Mortality from both coronary heart disease and all causes was significantly reduced for those with the highest vitamin K levels. Additionally, severe aortic calcification was decreased in those with high vitamin K2 intake, while low vitamin K intake was associated with an increased risk of dying from coronary heart disease.
The study results suggest that vitamin K2 helps protect against coronary heart disease in older adults without increasing the risk of other diseases, as demonstrated by the decrease in all-cause mortality associated with higher vitamin K2 intake.
* Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. Nutr. 2004 Nov;134(11):3100-5.
Research on ways to prevent the muscle wasting that plagues astronauts during space flight has led to a new treatment benefiting patients confined to bed rest. Scientists at the University of Texas Medical Branch at Galveston discovered that adding supplemental amino acids and carbohydrates to patients’ diets during bed rest prevents loss of muscle mass and strength.*
For their current study, they recruited 13 young, healthy men and randomly assigned them to two groups. One group was fed a normal diet and liquid placebo three times daily, while the second group was fed a normal diet and three supplement-fortified beverages containing essential amino acids and carbohydrates. Both groups were confined to bed rest for 28 days.
By the end of the test period, those receiving supplemental nutrients had retained all of their leg muscle mass, while the control subjects lost an average of one pound of leg muscle. Although all subjects lost some muscle strength, those receiving supplements experienced only half as much loss as the control subjects. Despite nearly a month without exercise, supplemented subjects lost no muscle mass.
The findings may lead to better treatments for elderly patients confined to bed rest, who often lose strength and muscle mass that may be difficult or impossible to recover. Elderly patients usually have less muscle mass than younger, healthier adults, and can ill afford additional losses, which usually prevent a full recovery.
* Paddon-Jones D, Sheffield-Moore M, Urban RJ, et al. Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. J Clin